
    
      The pilot study will utilize a prospective, randomized design. After meeting the
      inclusion/exclusion criteria and providing written informed consent, patients will be
      randomly assigned to a 30 % ethanol/ 4% sodium citrate locking solution or heparin 1000 U/ml.
      Patients will be enrolled from the Health Sciences Centre and the Sherbrook Dialysis Units in
      Winnipeg, Manitoba, Canada.
    
  